OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
OKYO Pharma Limited has initiated its first Phase 2 clinical trial for OK-101, a novel non-opioid treatment designed to address neuropathic corneal pain, a condition lacking FDA-approved therapies. The trial, involving 48 patients, aims to explore the safety and efficacy of OK-101, potentially offering a breakthrough for patients suffering from the debilitating effects of corneal nerve damage. With this step, OKYO Pharma takes a significant move towards providing a much-needed therapeutic option in ophthalmology.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.